Medical records for a DLBCL consultation in China: a practical preparation guide

A DLBCL second opinion is difficult when the record consists of one diagnostic screenshot, several PET photographs and a recollection of chemotherapy. The clinician needs to know how pathology was established, where disease began, which drugs and doses were actually given and when response or relapse occurred. An organized history lets the consultation focus on the current decision and can reduce avoidable repeat testing. [S1,S2,S3]

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Include full name, date of birth, complete diagnosis, diagnosis date, treatment stage, recent symptoms, current medicines and the opinion requested. Examples include pathology review, first-line choice, uncertain residual PET, CAR T eligibility or transplant assessment. A request to read everything does not identify the decision as clearly.
Supply current and relevant baseline counts, chemistry, LDH, cardiac testing and infection results, with units and reference intervals. Include individual hepatitis B tests, relevant viral results and antivirals. Serious infection, infusion reaction, neurological toxicity, thrombosis or kidney injury requires the corresponding clinical record. [S3,S8]
A trial may need more detailed previous drugs, washout, lesion measurements and organ results. Provide protocol-specific information; extra research sampling requires consent and should not be described as an ordinary mandatory investigation. [S16,S17] Failing one study's criteria does not establish that no standard treatment exists.

Quick answer

Full guide

You do not need to translate hundreds of pages before contacting a center. Start with a one-page summary and key originals, clearly identifying missing items. The summary provides navigation; the originals provide verification. Deteriorating illness still needs local care while documents are assembled.

Make the first page explain the clinical question

Include full name, date of birth, complete diagnosis, diagnosis date, treatment stage, recent symptoms, current medicines and the opinion requested. Examples include pathology review, first-line choice, uncertain residual PET, CAR T eligibility or transplant assessment. A request to read everything does not identify the decision as clearly.

List major conditions such as heart failure, kidney disease, hepatitis B, diabetes, neuropathy and allergies. Describe function through actual activities rather than inventing a performance score. Identify pending reports and the local clinician. This helps the receiving team decide what it can assess and what information is needed next. [S3]

Include every pathology supplement

Provide sampling date, site, method, diagnostic conclusion, immunohistochemistry, FISH and other molecular results. MYC/BCL2 protein expression differs from gene rearrangement, so methods must remain visible. Arrange outside reviews chronologically and identify the latest integrated opinion rather than keeping only the least alarming version. [S2]

Retain not tested, negative, insufficient sample and indeterminate exactly as written. Mediastinal, high-grade, indolent-component and transformation wording may affect treatment. Record if tissue was obtained after steroids or other therapy. Removing these details for brevity can change the clinical meaning.

Arrange slide and block access in advance

The originating laboratory has release procedures, and the receiving laboratory has material requirements. Confirm whether it needs stained slides, unstained sections, blocks or digital pathology. Quantity, preservation and destination should be agreed between departments rather than copied from online instructions. [S2]

Record the pathology number, owning institution and contact, with a loan and return inventory. Cross-border handling requirements should be checked by the relevant services. If tissue is limited, let the receiving team prioritize tests rather than distributing the material to several places without tracking what remains.

Obtain both DICOM images and reports

Collect pretreatment, interim, end-of-treatment and relapse imaging in date order. DICOM contains complete image and technical information; the report gives the original interpretation. Selected pictures cannot replace the full sequences for disease mapping, response or radiation planning. [S3]

Label each scan by treatment phase and note recent infection, growth-factor use or procedures. Keep the native format instead of converting everything into a low-resolution PDF. Test that files open and use the hospital's transfer route. Retain a family copy if discs or storage devices are handed over.

Record administered doses rather than abbreviations alone

For each line, list generic drugs, combination, start and end, actual doses, cycles, oral-treatment dates and support. R-CHOP alone does not show a doxorubicin reduction, vincristine omission or infection delay. If the regimen changed, identify progression, toxicity or another reason. [S20]

Ask a pharmacist to match brand and generic names for international use. Prescriptions and administration sheets support accuracy. Information reconstructed from memory should be marked for confirmation. Preserve formulation and route, and do not merge medicines because their names or drug classes appear similar.

Date the evidence of response and relapse

State the best response to each line, assessment date and supporting imaging or pathology. Persistent inadequate control differs from relapse after a complete response. Certain CAR T indications depend on the interval after first-line treatment, making the last treatment and relapse dates important. [S5]

An uncertain PET should remain uncertain in the summary rather than becoming confirmed recurrence. Note whether repeat biopsy is planned and its site. In someone with an indolent component, the new lesion may need histological clarification. A timeline is more useful than an undated series of positive results.

Do not omit infection, organ function or serious toxicity

Supply current and relevant baseline counts, chemistry, LDH, cardiac testing and infection results, with units and reference intervals. Include individual hepatitis B tests, relevant viral results and antivirals. Serious infection, infusion reaction, neurological toxicity, thrombosis or kidney injury requires the corresponding clinical record. [S3,S8]

A statement that chemotherapy was tolerated does not replace these details. For allergy, identify the medicine, symptoms and management. If fever after immune treatment was classified as cytokine release syndrome, record the grade or description and treatment. Unfavorable history should not be removed to make hospital acceptance appear easier.

Keep radiation, procedure and access information distinct

Radiation records include field, total dose, fractions, dates and how to obtain plan data. Operations or interventions need the procedure, tissue, complications and recovery. Venous-access records should identify the device, insertion, maintenance, infection and thrombosis history so a new team can use it appropriately. [S18]

For gastrointestinal disease, include endoscopy and bleeding or perforation records. Neurological evaluation may add MRI and cerebrospinal fluid cytology or flow. Collect what actually occurred; do not repeat an unindicated investigation merely to fill every box on a checklist. The receiving clinician determines which omissions matter.

Add the specialist details for transplantation and CAR T cells

An autologous transplant record should contain salvage response, mobilization, collection, conditioning, infusion and complications. Allogeneic transplantation introduces donor and immune details that should not be assumed for an autologous procedure. Correctly identify the type to avoid mistaken risk assessment. [S13]

CAR T documentation should specify product, collection and infusion dates, manufacturing result, bridging, lymphodepletion, cytokine release syndrome, neurotoxicity, management, persistent cytopenias and infection. [S11] Immune-cell treatment is not a sufficient description. For a bispecific, supply step-up, actual doses, last administration and adverse effects. [S6,S7]

Translate uncertainty and units accurately

Keep the original with a corresponding translation. Protein expression, rearrangement, fusion and mutation are different concepts and should not all become gene positive. Response, complete metabolic response and cure also differ. Check every value, reference interval and unit.

Mark illegible or missing text and request clarification rather than guessing. Date and language in the title help navigation. For consent, research and serious risk discussions, professional interpreting can help the patient understand directly instead of relying only on a simplified family account. [S16]

Use a simple stable electronic structure

Separate summary, pathology, imaging, treatment, laboratory, admissions/procedures and other records. Start filenames with dates, followed by institution and test or regimen. An index can identify final and pending documents. Do not add speculative conclusions such as definite relapse to an uncertain scan's filename.

Check identity across documents before transfer and ask a relative to help if needed. Use the official receiving channel and share with people involved in care rather than posting the full record publicly. A center needing preliminary review may initially require only key pages, with the rest supplied later on request.

Let the record review define additional time and expense

The hospital can identify whether slide review, FISH, new imaging or repeat sampling is necessary. Turnaround should be given by task rather than a promise that all work will finish within a few days before records are complete. Ask which missing items prevent a treatment decision and which can follow. [S2]

In Chinese yuan, separate remote review, shipping, translation, new tests and in-person assessment. No individualized quotation was verified here, so there is no universal records-package fee. Complete originals may reduce duplication but cannot guarantee that no tests will be repeated. [S10] Urgent treatment decisions remain the clinician's responsibility while documentation proceeds.

Prepare separate summaries for research and home care

A trial may need more detailed previous drugs, washout, lesion measurements and organ results. Provide protocol-specific information; extra research sampling requires consent and should not be described as an ordinary mandatory investigation. [S16,S17] Failing one study's criteria does not establish that no standard treatment exists.

Before leaving China, update the summary with final diagnosis, actual doses, response, complications, unresolved problems, infection medicines, access care and the next reviews. Give the home doctor originals as well. [S12] The record should evolve with treatment; its purpose is accurate transfer of responsibility, not simply obtaining an appointment.

Before the consultation, make a short missing-information log with the document, where it can be obtained and who is following it up. A pending FISH report should have a laboratory reference, while a missing administration sheet should be requested from the treating unit rather than reconstructed solely from invoices. When an updated report arrives, preserve the earlier version and mark which one supersedes it. If two documents appear inconsistent, flag the discrepancy for the clinician instead of editing the text to make them agree. This small record of uncertainty helps prevent an apparently tidy summary from concealing a clinically important gap.